Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy
dc.contributor.author | Ozyigit, Gokhan | |
dc.contributor.author | Onal, Cem | |
dc.contributor.author | Igdem, Sefik | |
dc.contributor.author | Alicikus, Zumre Arican | |
dc.contributor.author | Iribas, Ayca | |
dc.contributor.author | Akin, Mustafa | |
dc.contributor.author | Akyol, Fadil | |
dc.date.accessioned | 2020-12-02T18:01:44Z | |
dc.date.available | 2020-12-02T18:01:44Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0179-7158 | |
dc.identifier.issn | 1439-099X | |
dc.identifier.uri | https://doi.org/10.1007/s00066-019-01476-z | |
dc.identifier.uri | http://hdl.handle.net/11446/3709 | |
dc.description | Aksu, Melek Gamze/0000-0001-9146-2531; CETIN, ILKNUR ALSAN/0000-0003-4206-6393; Dincbas, Fazilet Oner/0000-0002-4764-9419 | en_US |
dc.description | WOS: 000511421900003 | en_US |
dc.description | PubMed: 31143994 | en_US |
dc.description.abstract | Purpose To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8-10 disease treated with external beam radiotherapy (EBRT)+ androgen deprivation therapy (ADT) in the modern era. Methods Institutional databases of biopsy proven 641 patients with GS 8-10 PCa treated between 2000 and 2015 were collected from 11 institutions. in this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. the inclusion criteria were, T1-T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70Gy total irradiation dose to prostate +/- seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT. Results the median follow-up time was 5.9 years (range 0.4-18.2 years); 5-year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (>= 78Gy) and longer ADT duration (>= 2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9-10. Conclusions Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9-10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving 'non-optimal treatment' (RT doses <78Gy and ADT period <2 years) had the worst treatment outcomes. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Heidelberg | en_US |
dc.identifier.doi | 10.1007/s00066-019-01476-z | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Pelvic radiotherapy | en_US |
dc.subject | Grading system | en_US |
dc.subject | Intensity modulated radiation therapy | en_US |
dc.subject | Hormonal treatment | en_US |
dc.subject | Androgen deprivation therapy | en_US |
dc.title | Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy | en_US |
dc.type | article | en_US |
dc.relation.journal | Strahlentherapie Und Onkologie | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.volume | 195 | en_US |
dc.identifier.startpage | 882 | en_US |
dc.identifier.endpage | 893 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Ozyigit, Gokhan; Hurmuz, Pervin; Akyol, Fadil] Hacettepe Univ, Fac Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey; [Onal, Cem; Guler, Ozan Cem] Baskent Univ, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, Adana, Turkey; [Igdem, Sefik] Istanbul Bilim Univ, Dept Radiat Oncol, Fac Med, Istanbul, Turkey; [Alicikus, Zumre Arican; Aydin, Barbaros; Gorken, Ilknur Birkay] Dokuz Eylul Univ, Dept Radiat Oncol, Fac Med, Izmir, Turkey; [Iribas, Ayca; Agaoglu, Fulya Yaman; Darendeliler, Emin] Istanbul Univ, Istanbul Oncol Inst, Dept Radiat Oncol, Istanbul, Turkey; [Akin, Mustafa] Balikesir State Hosp, Balikesir, Turkey; [Yalman, Deniz; Sert, Fatma; Ozkok, Serdar] Ege Univ, Dept Radiat Oncol, Fac Med, Izmir, Turkey; [Cetin, Ilknur] Marmara Univ, Dept Radiat Oncol, Fac Med, Istanbul, Turkey; [Aksu, Melek Gamze; Korcum, Aylin Fidan] Akdeniz Univ, Dept Radiat Oncol, Fac Med, Antalya, Turkey; [Atalar, Banu] Acibadem Univ, Dept Radiat Oncol, Fac Med, Istanbul, Turkey; [Dincbas, Fazilet; Yildirim, Cumhur] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Radiat Oncol, Istanbul, Turkey; [Yuce, Deniz] Hacettepe Univ, Hacettepe Canc Inst, Dept Prevant Oncol, Ankara, Turkey | en_US |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
PubMed İndeksli Yayınlar Koleksiyonu [1488]
PubMed Indexed Publications Collection -
Scopus İndeksli Yayınlar Koleksiyonu [1747]
Scopus Indexed Publications Collection -
WoS İndeksli Yayınlar Koleksiyonu [2110]
WoS Indexed Publications Collection